General Information of the Protein
Protein ID
PT01055
Protein Name
Serine/threonine-protein kinase PLK2
Secondarily
Protein Name
Polo-like kinase 2
Serine/threonine-protein kinase SNK
Serum-inducible kinase
Gene Name
PLK2
Secondarily
Gene Name
SNK
Sequence
MELLRTITYQPAASTKMCEQALGKGCGADSKKKRPPQPPEESQPPQSQAQVPPAAPHHHHHHSHSGPEISRIIVDPTTGKRYCRGKVLGKGGFAKCYEMTDLTNNKVYAAKIIPHSRVAKPHQREKIDKEIELHRILHHKHVVQFYHYFEDKENIYILLEYCSRRSMAHILKARKVLTEPEVRYYLRQIVSGLKYLHEQEILHRDLKLGNFFINEAMELKVGDFGLAARLEPLEHRRRTICGTPNYLSPEVLNKQGHGCESDIWALGCVMYTMLLGRPPFETTNLKETYRCIREARYTMPSSLLAPAKHLIASMLSKNPEDRPSLDDIIRHDFFLQGFTPDRLSSSCCHTVPDFHLSSPAKNFFKKAAAALFGGKKDKARYIDTHNRVSKEDEDIYKLRHDLKKTSITQQPSKHRTDEELQPPTTTVARSGTPAVENKQQIGDAIRMIVRGTLGSCSSSSECLEDSTMGSVADTVARVLRGCLENMPEADCIPKEQLSTSFQWVTKWVDYSNKYGFGYQLSDHTVGVLFNNGAHMSLLPDKKTVHYYAELGQCSVFPATDAPEQFISQVTVLKYFSHYMEENLMDGGDLPSVTDIRRPRLYLLQWLKSDKALMMLFNDGTFQVNFYHDHTKIIICSQNEEYLLTYINEDRISTTFRLTTLLMSGCSSELKNRMEYALNMLLQRCN
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Enzyme
>
Kinase
>
Protein Kinase
>
Other protein kinase group
>
Other protein kinase PLK family
>
Other protein kinase PLK2
Function
Tumor suppressor serine/threonine-protein kinase involved in synaptic plasticity, centriole duplication and G1/S phase transition. Polo-like kinases act by binding and phosphorylating proteins that are already phosphorylated on a specific motif recognized by the POLO box domains. Phosphorylates CENPJ, NPM1, RAPGEF2, RASGRF1, SNCA, SIPA1L1 and SYNGAP1. Plays a key role in synaptic plasticity and memory by regulating the Ras and Rap protein signaling: required for overactivity-dependent spine remodeling by phosphorylating the Ras activator RASGRF1 and the Rap inhibitor SIPA1L1 leading to their degradation by the proteasome. Conversely, phosphorylates the Rap activator RAPGEF2 and the Ras inhibitor SYNGAP1, promoting their activity. Also regulates synaptic plasticity independently of kinase activity, via its interaction with NSF that disrupts the interaction between NSF and the GRIA2 subunit of AMPARs, leading to a rapid rundown of AMPAR-mediated current that occludes long term depression. Required for procentriole formation and centriole duplication by phosphorylating CENPJ and NPM1, respectively. Its induction by p53/TP53 suggests that it may participate in the mitotic checkpoint following stress.
    Show/Hide
Uniprot ID
Primary ID:
Q9NYY3

Secondarily ID:
O60679
Q96CV7
Q9UE61
    Show/Hide
Ensembl ID
ENSG00000145632
HGNC ID
HGNC:19699
Subcellular Location
Cytoplasm
Cytoskeleton
Microtubule organizing center
Centrosome
Centriole
Cell projection
Dendrite
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000006 , HEK293
Compound ID Compound Name Compound Formula
CP0021461
(7R)-7-ethyl-2-[2-(4-fluorophenyl)imidazol-1-yl]-5-methyl-8-(1-methylpyrazol-3-yl)-7H-pteridin-6-one
   Show/Hide
C22H21FN8O
 1
1
IC50 = 480 nM
   TI
   LI
   LO
   TS
CP0248815
7-ethyl-2-[2-(4-fluorophenyl)imidazol-1-yl]-5-methyl-8-(1H-pyrazol-5-yl)-7H-pteridin-6-one
   Show/Hide
C21H19FN8O
 1
1
IC50 = 740 nM
   TI
   LI
   LO
   TS
CP0261084
(7R)-7-ethyl-2-[2-(4-fluorophenyl)imidazol-1-yl]-5-methyl-8-(1-methylpyrazol-4-yl)-7H-pteridin-6-one
   Show/Hide
C22H21FN8O
 1
1
IC50 = 780 nM
   TI
   LI
   LO
   TS
CP0088101
(7R)-7-ethyl-2-[2-(4-fluorophenyl)imidazol-1-yl]-5-methyl-8-(1H-pyrazol-4-yl)-7H-pteridin-6-one
   Show/Hide
C21H19FN8O
 1
1
IC50 = 1870 nM
   TI
   LI
   LO
   TS
CP0120617
(7R)-7-ethyl-2-[2-(4-fluorophenyl)imidazol-1-yl]-5-methyl-8-[(3S)-oxolan-3-yl]-7H-pteridin-6-one
   Show/Hide
C22H23FN6O2
 1
1
IC50 = 2050 nM
   TI
   LI
   LO
   TS
CP0220986
(7R)-7-ethyl-2-[2-(4-fluorophenyl)imidazol-1-yl]-5-methyl-8-(3,3,3-trifluoropropyl)-7H-pteridin-6-one
   Show/Hide
C21H20F4N6O
 1
1
IC50 = 2560 nM
   TI
   LI
   LO
   TS
CP0108841
(7R)-7-ethyl-5-methyl-8-(oxan-4-yl)-2-[5-(1,3-thiazol-2-yl)-1H-pyrazol-4-yl]-7H-pteridin-6-one
   Show/Hide
C20H23N7O2S
 1
1
IC50 = 2990 nM
   TI
   LI
   LO
   TS
CP0056992
(7R)-7-ethyl-5-methyl-8-[(3S)-oxolan-3-yl]-2-[5-(1,3-thiazol-2-yl)-1H-pyrazol-4-yl]-7H-pteridin-6-one
   Show/Hide
C19H21N7O2S
 1
1
IC50 = 3190 nM
   TI
   LI
   LO
   TS
CP0911900
rac-7-ethyl-5-methyl-2-(2-phenyl-1H-imidazol-1-yl)-8-(pyrimidin-5-yl)-7,8-dihydropteridin-6(5H)-one
   Show/Hide
C22H20N8O
 1
1
IC50 = 3870 nM
   TI
   LI
   LO
   TS
CP0220983
(7R)-7-ethyl-5-methyl-8-(1H-pyrazol-4-yl)-2-[5-(1,3-thiazol-2-yl)-1H-pyrazol-4-yl]-7H-pteridin-6-one
   Show/Hide
C18H17N9OS
 1
1
IC50 = 5820 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0021461
(7R)-7-ethyl-2-[2-(4-fluorophenyl)imidazol-1-yl]-5-methyl-8-(1-methylpyrazol-3-yl)-7H-pteridin-6-one
   Show/Hide
C22H21FN8O
 1
1 IC50 = 7 nM
CP0248815
7-ethyl-2-[2-(4-fluorophenyl)imidazol-1-yl]-5-methyl-8-(1H-pyrazol-5-yl)-7H-pteridin-6-one
   Show/Hide
C21H19FN8O
 1
1 IC50 = 9 nM
CP0088101
(7R)-7-ethyl-2-[2-(4-fluorophenyl)imidazol-1-yl]-5-methyl-8-(1H-pyrazol-4-yl)-7H-pteridin-6-one
   Show/Hide
C21H19FN8O
 1
1 IC50 = 12 nM
CP0261084
(7R)-7-ethyl-2-[2-(4-fluorophenyl)imidazol-1-yl]-5-methyl-8-(1-methylpyrazol-4-yl)-7H-pteridin-6-one
   Show/Hide
C22H21FN8O
 1
1 IC50 = 21 nM
CP0120617
(7R)-7-ethyl-2-[2-(4-fluorophenyl)imidazol-1-yl]-5-methyl-8-[(3S)-oxolan-3-yl]-7H-pteridin-6-one
   Show/Hide
C22H23FN6O2
 1
1 IC50 = 33 nM
CP0108841
(7R)-7-ethyl-5-methyl-8-(oxan-4-yl)-2-[5-(1,3-thiazol-2-yl)-1H-pyrazol-4-yl]-7H-pteridin-6-one
   Show/Hide
C20H23N7O2S
 1
1 IC50 = 36 nM
CP0056992
(7R)-7-ethyl-5-methyl-8-[(3S)-oxolan-3-yl]-2-[5-(1,3-thiazol-2-yl)-1H-pyrazol-4-yl]-7H-pteridin-6-one
   Show/Hide
C19H21N7O2S
 1
1 IC50 = 39 nM
CP0220986
(7R)-7-ethyl-2-[2-(4-fluorophenyl)imidazol-1-yl]-5-methyl-8-(3,3,3-trifluoropropyl)-7H-pteridin-6-one
   Show/Hide
C21H20F4N6O
 1
1 IC50 = 42 nM
CP0220983
(7R)-7-ethyl-5-methyl-8-(1H-pyrazol-4-yl)-2-[5-(1,3-thiazol-2-yl)-1H-pyrazol-4-yl]-7H-pteridin-6-one
   Show/Hide
C18H17N9OS
 1
1 IC50 = 92 nM
CP0338318
[(2R,3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-acetylpyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-3-[3-(8-phenyloctyl)imidazol-4-yl]propanoyl]amino]-3-hydroxypropanoyl]amino]-4-amino-4-oxobutan-2-yl] dihydrogen phosphate
   Show/Hide
C40H63N8O11P
 1
1 IC50 = 570 nM
Clinical Information about the Protein
Target 1 ( Polo-like kinase 2 (PLK2) )
Target Type Patented-recorded Target